Trials / Active Not Recruiting
Active Not RecruitingNCT05399654
A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Tallac Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
INCLINE-101 is an open label, multicenter Phase 1/2 study designed to evaluate safety, pharmacokinetics (PK), and preliminary anti-tumor activity of TAC-001 administered intravenously.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAC-001 | TAC-001 is a Toll-like Receptor Agonist Antibody Conjugate (TRAAC) |
Timeline
- Start date
- 2022-06-28
- Primary completion
- 2026-01-27
- Completion
- 2026-05-19
- First posted
- 2022-06-01
- Last updated
- 2024-08-16
Locations
12 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05399654. Inclusion in this directory is not an endorsement.